TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML

Autor:	Aminetou Mint, Mohamed, Marie, Balsat, Catherine, Koering, Delphine, Maucort-Boulch, Nicolas, Boissel, Lea, Payen-Gay, Meyling, Cheok, Hussein, Mortada, Didier, Auboeuf, Christiane, Pinatel, Mohamed, El-Hamri, Isabelle, Tigaud, Sandrine, Hayette, Charles, Dumontet, Emeline, Cros, Pascale, Flandrin-Gresta, Olivier, Nibourel, Claude, Preudhomme, Xavier, Thomas, Franck-Emmanuel, Nicolini, Françoise, Solly, Denis, Guyotat, Lydia, Campos, Mauricette, Michallet, Antony, Ceraulo, Franck, Mortreux, Eric, Wattel
Rok vydání:	2016
Předmět:	Male Age Factors Exons Middle Aged Prognosis Risk Assessment Disease-Free Survival Dioxygenases DNA-Binding Proteins Cytogenetics Leukemia Myeloid Acute fms-Like Tyrosine Kinase 3 Proto-Oncogene Proteins Humans Female Nucleophosmin
Zdroj:	Leukemia research. 56
ISSN:	1873-5835
Popis:	In AML, approximately one-third of expressed genes are abnormally spliced, including aberrant TET2 exon 2 expression. In a discovery cohort (n=99), TET2 exon 2 skipping (TET2E2S) was found positively associated with a significant reduction in the cumulative incidence of relapse (CIR). Age, cytogenetics, and TET2E2S were independent prognostic factors for disease-free survival (DFS), and favorable effects on outcomes predominated in cytogenetic normal (CN)-AML and younger patients. Using the same cutoff in a validation cohort of 86 CN-AML patients, TET2E2S
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::ff326d24c3adddd7044ff2b1f02eff8a https://pubmed.ncbi.nlm.nih.gov/28167452 Zobrazit plný text záznamu Full Text from ScienceDirect